Summary
Beigene, Ltd. (ONC) has filed a Form 8-K detailing significant progress across its oncology pipeline and strategic partnerships. Key developments include the acceptance of a supplemental Biologics License Application (sBLA) in China for tislelizumab, an anti-PD-1 antibody, for the treatment of specific solid tumors (MSI-H/dMMR). This regulatory step in a major market signifies a potential expansion for a key asset. Furthermore, the company announced a significant strategic collaboration with Shoreline Biosciences to develop and commercialize next-generation NK-based cell therapeutics utilizing Shoreline's iPSC NK cell technology. This partnership aims to leverage BeiGene's R&D and clinical capabilities to create innovative cell therapies for various malignancies. The report also highlights positive clinical data presented at the EHA2021 Virtual Congress, showcasing long-term efficacy and safety results for tislelizumab in classical Hodgkin's lymphoma and for its BTK inhibitor BRUKINSA® (zanubrutinib) in mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma. Notably, the ALPINE Phase 3 trial results demonstrated superiority of BRUKINSA® over ibrutinib in a head-to-head comparison for relapsed/refractory CLL/SLL, including key efficacy and safety endpoints.
Key Highlights
- 1China's NMPA accepted a supplemental BLA for tislelizumab in MSI-H/dMMR solid tumors.
- 2Exclusive worldwide collaboration established with Shoreline Biosciences to develop iPSC NK cell therapies.
- 3Long-term follow-up results for tislelizumab in classical Hodgkin's lymphoma presented at EHA2021.
- 4Pivotal Phase 2 trial results for BRUKINSA® (zanubrutinib) in R/R mantle cell lymphoma and CLL/SLL presented at EHA2021.
- 5Phase 3 ALPINE trial results show BRUKINSA® superior to ibrutinib in R/R CLL/SLL for overall response rate and atrial fibrillation.
- 6The Alpine trial results also indicate potential safety advantages for BRUKINSA® compared to ibrutinib.